image description

Cell and Gene Therapy

30th and 31st July, 2020 @ 08:30 - 05:00 PM EST
10+ Speakers
18+Hours
10+Sessions
350+Attendees
Register Now Become a Speaker

Event   Details


Cell and Gene therapy (CGT) is considered as one of the most progressive advancements in this new ecosystem with extensive evaluations of multiple diseases and upcoming technologies. With the ongoing enhancements in CGT the potential to transform medicine increases which has brought a significant change for the treatment and potential cure of many intractable illnesses. In recent years, these therapies have proved clinically to be life-saving and also promise to offer personalization treatment for several diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.

Cell and Gene therapy continues to be a prominent and active area of research in genomics and cell biology which have permitted exciting progress in the development of novel and effective treatments for various diseases. With cell and gene therapies finally becoming a reality with ongoing hundreds of clinical trials and some of the major therapeutics breakthroughs already reaching the market, it is expected soon their will large number of approvals and launches in the market. So let’s come together to discuss the future of cell and gene therapy along with their applications, challenges and regulatory scenario.

In the pioneer edition of DBMR Cell and Gene Therapy Conference come join us in this enriching knowledge fest where experts will speak on new technologies and market dynamics perceptions. Together let’s move ahead in the future of medical science and technology.

Register Now Become a Speaker

Key Highlights

Key Highlights

Who Should Attend?

Who Should Attend?

Why Attend?

Why Attend?

Our Speakers


Conference Program


8:30 AM EST

Registration (Telephonic and Virtual)

9:30 AM EST

Introduction to DBMR

9:30 AM EST

Opening Speech

Ruchika Kakarya.

Senior Manager - Research and Consulting

10:00 AM EST

Market Access for Cell & Cell Therapies

Guvenc Kockaya

Management Troika
ECONiX

10:15 PM EST

Cell & Gene Therapy Manufacturing Pathway

11:00 AM EST

Gene Therapy targeting Neuregulins for the treatment of Amyotrophic Lateral Sclerosis

Dr. Guillem Mòdol Caballero

Researcher
MRC Laboratory for Molecular Cell Biology (LMCB), UCL

12:00 PM EST

Modified mRNA based Gene Therapy: The next frontier

Keerat Kaur

Researcher - Department of Cardiology
Icahn School of Medicine at Mount Sinai

1:00 PM EST

Break/Exhibit

2:30 PM EST

One on One Networking Break

03:00 PM EST

Cell And Gene Therapy- Applications, Regulations And Compliance

Dr. Mohamad Toutounji

Founder and CEO
Molgenium

04:00 PM EST

The Potential of Gene and Cell Therapies for Muscular Dystrophies

Sridhar Selvaraj

Researcher
Stanford University School of Medicine

4:30 PM EST

Cell and Gene Therapy:Strategies for the Commercialization

5:00 PM EST

DBMR Quantum Leap Awards

8:30 AM EST

Registration (Telephonic and Virtual)

9:30 AM EST

Keynote Speech The Future Of Cell and Gene Therapy

10:15 AM EST

Cell and Gene TherapyApplications,Regulations And Compliance

11:30 AM EST

One on One Networking Break

12:00 PM EST

Looking beyond HSCT: How Cell and gene therapy is shaping the future of post Stem cell transplantations

Michael Schenk

Advanced Specialist Biomedical Scientist
Imperial College London

1:00 PM CET

Break/Exhibit

2:00 PM EST

Successful Development of Quality Cell and Gene Therapy Products

3:00 PM EST

Commercial Trailblazers in Cell and Gene Therapy Sector

3:30 PM EST

Effect of Reimbursement on Cell and Gene Therapy Treatment

4:00 PM EST

Looking towards the future of Cell and Gene Therapy

Arun Srivastava

George H. Kitzman Professor of Genetics
University of Florida College of Medicine
Division Chief
Cellular and Molecular Therapy, Powell Gene Therapy Center

5:00 PM EST

DBMR Closing Remarks